154 related articles for article (PubMed ID: 29609548)
1. Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic.
Tomczyk S; Lessa FC; Sánchez J; Peña C; Fernández J; Gloria Carvalho M; Pimenta F; Cedano D; Whitney CG; Verani JR; Coradin H; Garib Z; De Oliveira LH; Feris-Iglesias J
BMC Infect Dis; 2018 Apr; 18(1):152. PubMed ID: 29609548
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: An indirect cohort study.
Andrejko KL; Gierke R; Rowlands JV; Rosen JB; Thomas A; Landis ZQ; Rosales M; Petit S; Schaffner W; Holtzman C; Barnes M; Farley MM; Harrison LH; McGee L; Chochua S; Verani JR; Cohen AL; Pilishvili T; Kobayashi M
Vaccine; 2024 Jun; 42(16):3555-3563. PubMed ID: 38704263
[TBL] [Abstract][Full Text] [Related]
3. High Prevalence of Vaccine-Type Infections Among Children with Pneumococcal Pneumonia and Effusion After 13-Valent Pneumococcal Conjugate Vaccine Introduction in the Dominican Republic.
Ahmed SS; Lessa FC; Coradin H; Sánchez J; Carvalho MDG; Soda E; Peña C; Fernández J; Cedano D; Whitney CG; Feris-Iglesias J
J Infect Dis; 2021 Sep; 224(12 Suppl 2):S228-S236. PubMed ID: 34469563
[TBL] [Abstract][Full Text] [Related]
4. Impact of 13-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage Rates of Streptococcus pneumoniae in a Rural Community in the Dominican Republic.
Dunn MG; Lessa FC; Sánchez J; Cordero R; Feris-Iglesias J; Cedano D; Carvalho MDG; Fernández J; Feemster KA
J Infect Dis; 2021 Sep; 224(12 Suppl 2):S237-S247. PubMed ID: 34469551
[TBL] [Abstract][Full Text] [Related]
5. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.
Domínguez Á; Ciruela P; Hernández S; García-García JJ; Soldevila N; Izquierdo C; Moraga-Llop F; Díaz A; F de Sevilla M; González-Peris S; Campins M; Uriona S; Martínez-Osorio J; Solé-Ribalta A; Codina G; Esteva C; Planes AM; Muñoz-Almagro C; Salleras L
PLoS One; 2017; 12(8):e0183191. PubMed ID: 28806737
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study.
Cohen C; von Mollendorf C; de Gouveia L; Lengana S; Meiring S; Quan V; Nguweneza A; Moore DP; Reubenson G; Moshe M; Madhi SA; Eley B; Hallbauer U; Finlayson H; Varughese S; O'Brien KL; Zell ER; Klugman KP; Whitney CG; von Gottberg A;
Lancet Glob Health; 2017 Mar; 5(3):e359-e369. PubMed ID: 28139443
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.
Deceuninck G; De Serres G; Boulianne N; Lefebvre B; De Wals P
Vaccine; 2015 May; 33(23):2684-9. PubMed ID: 25887086
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.
Savulescu C; Krizova P; Valentiner-Branth P; Ladhani S; Rinta-Kokko H; Levy C; Mereckiene J; Knol M; Winje BA; Ciruela P; de Miguel S; Guevara M; MacDonald L; Kozakova J; Slotved HC; Fry NK; Pekka Nuorti J; Danis K; Corcoran M; van der Ende A; Vestrheim DF; Munoz-Almagro C; Sanz JC; Castilla J; Smith A; Colzani E; Pastore Celentano L; Hanquet G;
Vaccine; 2022 Jun; 40(29):3963-3974. PubMed ID: 35637067
[TBL] [Abstract][Full Text] [Related]
10. Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study.
Ricketson LJ; Bettinger JA; Sadarangani M; Halperin SA; Kellner JD;
Vaccine; 2022 Apr; 40(19):2733-2740. PubMed ID: 35351324
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
[TBL] [Abstract][Full Text] [Related]
12. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study.
Kim JH; Chun BC; Song JY; Kim HY; Bae IG; Kim DM; Choi YH; Jun YH; Choi WS; Kang SH; Kwon HH; Jeong HW; Kee SY; Hur J; Chung JW; Yoon YK; Sohn JW; Yang KS; Kim MJ
Vaccine; 2019 May; 37(21):2797-2804. PubMed ID: 31005428
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Pneumococcal Conjugate Vaccines of Different Valences Against Invasive Pneumococcal Disease Among Children in Taiwan: A Nationwide Study.
Su WJ; Lo HY; Chang CH; Chang LY; Chiu CH; Lee PI; Lu CY; Hsieh YC; Lai MS; Lin TY
Pediatr Infect Dis J; 2016 Apr; 35(4):e124-33. PubMed ID: 26974752
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines in a Schedule Without a Booster Dose: A 10-Year Observational Study.
Jayasinghe S; Chiu C; Quinn H; Menzies R; Gilmour R; McIntyre P
Clin Infect Dis; 2018 Jul; 67(3):367-374. PubMed ID: 29471432
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany.
van der Linden M; Falkenhorst G; Perniciaro S; Fitzner C; Imöhl M
PLoS One; 2016; 11(8):e0161257. PubMed ID: 27526117
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study.
Moore MR; Link-Gelles R; Schaffner W; Lynfield R; Holtzman C; Harrison LH; Zansky SM; Rosen JB; Reingold A; Scherzinger K; Thomas A; Guevara RE; Motala T; Eason J; Barnes M; Petit S; Farley MM; McGee L; Jorgensen JH; Whitney CG
Lancet Respir Med; 2016 May; 4(5):399-406. PubMed ID: 26987984
[TBL] [Abstract][Full Text] [Related]
18. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
Farnham AC; Zimmerman CM; Papadouka V; Konty KJ; Zucker JR; Nattanmai GV; Jose S; Rosen JB
JAMA Pediatr; 2015 Jul; 169(7):646-52. PubMed ID: 25938798
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-serotype community acquired pneumococcal diseases among children in China: A test-negative case-control study.
Xiaofei L; Yudan LI; Qinghui C; Jiaming S; Benfeng Z; Youyi Z; Biying W; Lijun Y; Jun Z; Jianmei T; Lin L; Xuejun S; Genming Z; Tao Z
Vaccine; 2024 Feb; 42(6):1275-1282. PubMed ID: 38296700
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P
Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
